Dishman Pharmaceuticals company Carbogen-Amcis AG to invest US$ 8 million

Dishman Pharmaceuticals & Chemicals Ltd has announced that Carbogen-Amcis AG, the Swiss Company recently acquired by the Company, announces a capital investment of US$ 8 million for their additional Oncology production line. The investment is being made because Carbogen-Amcis' capacity is fully augmented as of now and two of its customer's Oncology products have successfully cleared phase-III and the customers will be filing market authorization in near future. The investment to be made will be out of Carbogen-Amcis’ cash accruals.

Source : Equity Bulls

Keywords